Full-Time

Principal Scientist

Analytical Bioassay Development

Posted on 9/23/2025

Voyager Therapeutics

Voyager Therapeutics

51-200 employees

Develops genetic medicines for neurological diseases

Compensation Overview

$156.8k - $205.8k/yr

Lexington, MA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Data Analysis
Requirements
  • PhD in molecular biology, cell biology or related field with 10+ years of industry experience OR Masters with 16+yrs experience OR BS with 17+ yrs experience
  • Strong expertise in molecular analytical techniques (ddPCR, dPCR, qPCR, short and long read sequencing)
  • Extensive experience with various analytical bioassays including cell-based, ELISA etc. for different modalities such as viral vectors, protein therapeutics
  • Knowledge of statistical data analysis for bioassays
  • Understanding of regulatory and compendial expectations for analytical methods, assay qualification and validation; experience supporting regulatory filings
  • Prior experience working with CROs/CDMOs is highly desirable
  • Knowledge of cGMP compliance requirements
  • Ability to handle multiple projects, meet deadlines and make decisions
  • Excellent organizational, writing, and communication skills
Responsibilities
  • Lead design, development, and qualification of various biological methods
  • Oversee transfer, execution, and troubleshooting of biological methods at contract research organizations (CROs)
  • Provide expertise on data analysis and evaluation of critical quality attributes of various drug candidates (AAV-based vectors, bispecific antibodies and antibody-oligonucleotide conjugates)
  • Author and review SOPs, analytical protocols, technical reports, and regulatory submission documents
  • Ensure quality of key results of major project plans through sound design, early risk assessments and mitigation. Track critical data and assay performance.
  • Interpret and present complex analytical data with clarity to internal stakeholders and externally
  • Mentor and/or supervise junior scientists, providing guidance on experimental design, troubleshooting, and career development
  • Closely collaborate with Process Development, Pilot Manufacturing, QA, and Research to support testing, data interpretation, and R2D transitions
Desired Qualifications
  • Prior experience working with CROs/CDMOs is highly desirable

Voyager Therapeutics develops genetic medicines for neurological diseases. Its focus is on delivering therapeutic genes to the brain by using a proprietary AAV (adeno-associated virus) capsid discovery platform that enables intravenous delivery across the blood-brain barrier. This allows targeted treatment for conditions like ALS and other central nervous system disorders. The company works mainly through research and development, forming partnerships and licensing deals with larger pharmaceutical companies to fund and accelerate bringing therapies to patients. Unlike many biotech firms that rely on a single approach, Voyager emphasizes a platform-based strategy to improve brain delivery and collaborates with partners to advance candidates through development and potentially to market. The overarching goal is to create meaningful, disease-modifying genetic medicines that can reach the brain and improve outcomes for people with neurological diseases.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $202M cash runway funds operations into 2028 for 2026 clinical milestones.
  • Q4 2025 collaboration revenue doubled to $15.3M from partnerships like Neurocrine.
  • Transition Bio deal adds TDP-43 small molecules for ALS/FTD with $500M milestones.

What critics are saying

  • Novartis returned two programs in November 2025, triggering 30 employee layoffs.
  • Pomerantz investigates securities fraud over February 2025 SOD1 ALS payload switch.
  • 2025 net loss widened to $120M from pipeline costs and ALS delays.

What makes Voyager Therapeutics unique

  • Proprietary TRACER AAV capsid platform enables IV brain delivery across blood-brain barrier.
  • Pipeline targets ALS, Parkinson's, Friedreich's ataxia, and tau/APOE in Alzheimer's.
  • Matches modalities like AAV gene therapy and small molecules to specific neurology targets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

7%
Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Yahoo Finance
Mar 13th, 2026
Voyager Therapeutics' annual loss widens to $120M despite Q4 improvement as neurology pipeline advances

Voyager Therapeutics reported a fourth-quarter 2025 net loss of $27.43 million, down from $34.49 million a year earlier. However, its full-year 2025 net loss widened to $119.72 million from $65.00 million, reflecting increased costs to advance its neurology-focused pipeline. The pre-revenue company's quarterly loss per share narrowed to $0.47 basic, whilst full-year loss per share increased to $2.04. The widening annual deficit highlights elevated cash burn and execution risk despite a November 2025 collaboration with Transition Bio on ALS and FTD treatments. Voyager depends heavily on milestone payments from pharmaceutical partnerships to fund its R&D. Some analysts project revenues reaching $138 million with positive earnings by 2028, though the company's current losses underscore significant uncertainty around this tau-focused pipeline.

Yahoo Finance
Mar 10th, 2026
Voyager Therapeutics beats Q4 revenue estimates by 58% with $15.34M, narrows loss to $0.46 per share

Voyager Therapeutics reported a quarterly loss of $0.46 per share for Q4 2025, beating the Zacks Consensus Estimate of a loss of $0.54 per share. This represents an earnings surprise of 15.08% and compares to a loss of $0.59 per share in the same quarter last year. The gene therapy company posted revenues of $15.34 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 57.97%. This compares to year-ago revenues of $6.28 million. The company has topped consensus revenue estimates twice over the last four quarters. Voyager shares have declined 0.8% since the beginning of the year, outperforming the S&P 500's 1.5% decline. The company currently holds a Zacks Rank 3 (Hold), suggesting shares are expected to perform in line with the market.

The Associated Press
Mar 9th, 2026
Voyager Therapeutics reports $202M cash runway into 2028, eyes tau therapies for Alzheimer's

Voyager Therapeutics reported fourth quarter and full year 2025 financial results, ending the year with a cash position of $202 million expected to maintain operations into 2028. The company anticipates 2026 will be pivotal, with clinical entry for tau-targeting Alzheimer's therapies VY1706 and VY7523 expected in the second half. Collaboration revenue reached $15.3 million in Q4 2025, up from $6.3 million in Q4 2024, though full-year revenue declined to $40.4 million from $80 million. Net loss for 2025 was $119.7 million compared to $65 million in 2024. Voyager expects to dose its first patient with VY1706 in H2 2026 and release tau PET imaging data for VY7523 during the same period. Partner Neurocrine plans to initiate clinical trials for Friedreich's ataxia therapy NBIB-'223 in H2 2026, pending FDA approval.

Fierce Biotech
Dec 17th, 2025
Voyager jettisons 30 employees, Novartis hands back rights to 2 programs

Voyager jettisons 30 employees, Novartis hands back rights to 2 programs. Neurology biotech Voyager Therapeutics has laid off 30 employees, a spokesperson for the Massachusetts-based company confirmed to Fierce Biotech. The layoffs come after the November announcement, tucked in Voyager's third-quarter earnings report, that Novartis has discontinued two discovery-stage programs from the pair's ongoing team-up, returning the rights to Voyager. Programs for Huntington's disease, spinal muscular atrophy and another undisclosed target were unaffected by the decision, Voyager said at the time. "Voyager evaluates its business needs on an ongoing basis to ensure it has the appropriate workforce and expertise to support its business goals," the spokesperson explained Wednesday. At the time of publication, Voyager had not responded to Fierce's questions about the number of employees left at the company or whether the layoffs are related to Novartis' decision to discontinue the programs. The biotech employs between 51 and 200 people, according to its LinkedIn page. Voyager has one clinical asset, a tau-targeting antibody in a phase 1 study for Alzheimer's disease. The biotech plans to launch another asset, a tau-silencing small interference RNA molecule called VY1706, into clinical trials next year, according to Voyager's third-quarter earnings report. The company is also pursuing a gene therapy for amyotrophic lateral sclerosis but had to delay its efforts on that front earlier this year to find a new payload. Also in November, Voyager took off on a new research collaboration with Transition Bio to discover and develop small molecules for neurodegenerative diseases. Voyager paid its new partner a single-digit million-dollar upfront payment, with additional payments up to $500 million possible if certain milestones are met. As of Sept. 30, Voyager had $229 million stored in its cargo, according to the earnings report.

INACTIVE